| scholarly article | Q13442814 |
| P2093 | author name string | A Cherkaoui | |
| P François | |||
| J Schrenzel | |||
| Q Haddad | |||
| S Al-Obeid | |||
| P2860 | cites work | A generic approach for the design of whole-genome oligoarrays, validated for genomotyping, deletion mapping and gene expression analysis on Staphylococcus aureus | Q24810651 |
| Whole genome sequencing of meticillin-resistant Staphylococcus aureus | Q28202807 | ||
| Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus | Q29619365 | ||
| Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages | Q30341876 | ||
| Rapid detection of the pandemic methicillin-resistant Staphylococcus aureus clone ST 239, a dominant strain in Asian hospitals. | Q30367475 | ||
| In vivo emergence of subpopulations expressing teicoplanin or vancomycin resistance phenotypes in a glycopeptide-susceptible, methicillin-resistant strain of Staphylococcus aureus | Q31830915 | ||
| Exploring glycopeptide-resistance in Staphylococcus aureus: a combined proteomics and transcriptomics approach for the identification of resistance-related markers. | Q33264418 | ||
| Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function | Q33883752 | ||
| Use of an automated multiple-locus, variable-number tandem repeat-based method for rapid and high-throughput genotyping of Staphylococcus aureus isolates | Q33885060 | ||
| Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals. | Q33963573 | ||
| Vancomycin-intermediate Staphylococcus aureus in Korea. | Q33970102 | ||
| First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand | Q33971217 | ||
| Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals | Q33974326 | ||
| Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections | Q34117827 | ||
| tcaA inactivation increases glycopeptide resistance in Staphylococcus aureus | Q34141289 | ||
| Molecular evolution of methicillin-resistant Staphylococcus aureus in the metropolitan area of Cologne, Germany, from 1984 to 1998. | Q34143675 | ||
| Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene | Q34188059 | ||
| Use of oligoarrays for characterization of community-onset methicillin-resistant Staphylococcus aureus | Q34431703 | ||
| Emergence, mechanism, and clinical implications of reduced glycopeptide susceptibility in Staphylococcus aureus | Q34471268 | ||
| Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing | Q34630593 | ||
| Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus | Q34747322 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| Trends in antibiotic susceptibility patterns and epidemiology of MRSA isolates from several hospitals in Riyadh, Saudi Arabia | Q35241405 | ||
| Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods | Q35541702 | ||
| Epidemiology of methicillin-resistant staphylococci in Europe. | Q35612051 | ||
| MRSA--the tip of the iceberg | Q36416464 | ||
| The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus | Q36779557 | ||
| Virulence determinants in community and hospital meticillin-resistant Staphylococcus aureus. | Q36836241 | ||
| Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). | Q36898180 | ||
| Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus | Q36932920 | ||
| Methicillin-resistant Staphylococcus aureus, Geneva, Switzerland, 1993-2005. | Q37008996 | ||
| Genomic analysis of an emerging multiresistant Staphylococcus aureus strain rapidly spreading in cystic fibrosis patients revealed the presence of an antibiotic inducible bacteriophage | Q37069059 | ||
| Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. | Q37333104 | ||
| Resistance to autolysis in vancomycin-selected Staphylococcus aureus isolates precedes vancomycin-intermediate resistance | Q39755460 | ||
| Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period | Q41066970 | ||
| Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center | Q41387835 | ||
| Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate- S. aureus-type resistance to vancomycin | Q41867637 | ||
| A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides | Q42912582 | ||
| Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility | Q43433837 | ||
| Trends of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae in Europe | Q43672322 | ||
| Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. | Q43834620 | ||
| Vancomycin-resistant Staphylococcus aureus--Pennsylvania, 2002. | Q44206422 | ||
| The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin | Q44235780 | ||
| Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. | Q44302673 | ||
| Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterization | Q44340945 | ||
| Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus | Q44674318 | ||
| Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin | Q44850137 | ||
| Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin | Q45199316 | ||
| Incidence of glycopeptide hetero-intermediate Staphylococcus aureus strains in Maltese hospitals | Q46429144 | ||
| Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. | Q46766488 | ||
| A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital | Q46802703 | ||
| Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia | Q46933141 | ||
| Molecular epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) isolates from major hospitals in Riyadh, Saudi Arabia | Q46979349 | ||
| National trends in Staphylococcus aureus infection rates: impact on economic burden and mortality over a 6-year period (1998-2003). | Q51108395 | ||
| Infective endocarditis. | Q52884139 | ||
| Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. | Q54095666 | ||
| Comparative Prevalence of Superantigen Genes in Staphylococcus aureus Isolates Causing Sepsis With and Without Septic Shock | Q58442172 | ||
| Relationship of staphylococcal tolerance, teichoic acid antibody, and serum bactericidal activity to therapeutic outcome in Staphylococcus aureus bacteremia | Q68887772 | ||
| [Staphylococcus aureus septicemia in children: bacterial tolerance to vancomycin and serum bactericidal activity] | Q71721323 | ||
| Vancomycin resistance among epidemic strains of methicillin-resistant Staphylococcus aureus in England and wales | Q73413803 | ||
| First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital | Q74716023 | ||
| The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan | Q74823194 | ||
| Use of antibiotics in the poultry industry in Saudi Arabia: implications for public health | Q79679482 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Saudi Arabia | Q851 |
| Staphylococcus aureus | Q188121 | ||
| P304 | page(s) | 2199-2204 | |
| P577 | publication date | 2010-04-14 | |
| P1433 | published in | Journal of Clinical Microbiology | Q4041880 |
| P1476 | title | First detection of an invasive Staphylococcus aureus strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia | |
| P478 | volume | 48 |
| Q38023661 | Antimicrobial resistance among Gram-positive pathogens in Saudi Arabia |
| Q98164449 | Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis |
| Q34933382 | Impact of ciprofloxacin exposure on Staphylococcus aureus genomic alterations linked with emergence of rifampin resistance |
| Q56045590 | Molecular Typing of ST239-MRSA-III From Diverse Geographic Locations and the Evolution of the SCC III Element During Its Intercontinental Spread |
| Q54328600 | Protective immunization against Staphylococcus aureus infection in a novel experimental wound model in mice. |
| Q64240023 | Report of β-lactam antibiotic-induced vancomycin-resistant from a university hospital in Egypt |
| Q38641810 | Susceptibility testing and reporting of new antibiotics with a focus on tedizolid: an international working group report |
| Q84922061 | Utility of the Etest GRD for detecting Staphylococcus aureus with reduced susceptibility to glycopeptides in cystic fibrosis patients |
Search more.